Treatment of vaginal candidiasis in pregnancy with a single clotrimazole 500 mg vaginal pessary

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
treatment_thmbnl
Detail Image
treatment_mbl
Book Detail
Upload PDF
treatment.pdf (1.9 MB)
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

A single 500 mg clotrimazole vaginal pessary was found highly effective in treating vaginal candidiasis during pregnancy, according to a prospective trial involving 46 women in their second and third trimesters. One week after treatment, 83.3% of patients were cured both microscopically and mycologically, and all reported relief of symptoms. The recurrence rate after one month was only 5.7%, and patients who required retreatment responded successfully to a second dose. The study reported no adverse effects and highlighted several benefits of single-dose therapy — effectiveness, safety, rapid symptom relief, high compliance, and low recurrence — making it a simple and reliable option for pregnant patients.

Published Date